McKesson

MCK

Market cap $121B

McKesson Corporation (MCK) shares up 58% in a year thanks to Big Money.

McKesson Corporation shares are now fairly valued after a 16% price increase, prompting a Hold rating. Strong Q3 results were driven by 11% revenue growth and a 37% surge in the Oncology & Multispeciality segment, aided by M&A. Management raised FY2026 guidance, with EPS now expected at $38.80–39.20 and revenue growth at 12–16%.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The Allspring Large Cap Growth Fund underperformed the Russell 1000 Growth Index during the fourth quarter. As VYVGART gains traction with new patients, argenx continues to advance its pipeline, targeting additional autoimmune disorders to further broaden its impact. With a record backlog and a global footprint, we believe that Johnson Controls is well positioned to capitalize on demand for energy-efficient solutions, digital building automation, and data center investments.

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

McKesson beats Q3 EPS and revenue estimates, raises fiscal 2026 guidance, and delivers broad-based growth led by oncology, specialty distribution and technology.

McKesson (MCK), a prominent pharmaceutical wholesaler, experienced a stock increase of 17% during a high-volume trading session. The driver for this surge was a strong Q3 earnings report that surpassed expectations and, more importantly, a significant rise in the full-year 2026 adjusted EPS forecast.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?